J&J scuttles PhIII lupus program on failed data analysis; Novartis pays $345M to resolve bribery charges
→ J&J’s high hopes for broadening the use of Stelara to cover systemic lupus erythematosus has foundered in Phase III. Researchers …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
